Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||BC8-B10 + Cyclophosphamide + Fludarabine|
BC8-B10 is a radioimmunoconjugate that contains anti-CD45 monoclonal antibody BC8 with its lysine side groups conjugated with decoborate and labeled with Astatine (NCI Drug Dictionary). BC8-B10 prolongs survival of mice with disseminated murine leukemia in conjugation with bone marrow transplant (PMID: 23471305).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|BC8-B10||astatine At 211 MAb BC8-B10|At 211 anti-CD45 BC8-B10|At 211 MAb BC8-B10||BC8-B10 is a radioimmunoconjugate that contains anti-CD45 monoclonal antibody BC8 with its lysine side groups conjugated with decoborate and labeled with Astatine (NCI Drug Dictionary).|
|Cyclophosphamide||Cytoxan||CPM||Chemotherapy - Alkylating 14||Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).|
|Fludarabine||Fludara||FAMP|Fludarabine phosphate||Flurdara (fludarabine) is converted to 2-fluoro-ara-ATP intracellularly, which potentially inhibits DNA polymerase alpha, ribonucleotide reductase and DNA primase, leading to decreased DNA synthesis and reduced tumor growth (NCI Drug Dictionary)|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03670966||Phase Ib/II||BC8-B10 + Cyclophosphamide + Fludarabine Cyclophosphamide + Filgrastim + Mycophenolate mofetil + Sirolimus + Tacrolimus||211At-BC8-B10 and Donor Stem Cell Transplant in Treating Relapsed or Refractory AML, ALL, or Myelodysplastic Syndrome||Recruiting|